版本:
中国

BRIEF-Bristol-Myers Squibb enters into separate agreements with Biogen and Roche

April 13 Bristol-myers Squibb Co

* Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to license anti-etau and anti-myostatin compounds, respectively

* Bristol-Myers Squibb Co - to receive a combined $470m upfront, along with potential milestone payments and tiered double-digit royalties from each company

* Bristol-Myers Squibb Co - under agreement to license BMS-986168, Biogen will pay to Bristol-Myers Squibb an upfront payment of $300 million

* Bristol-Myers Squibb Co - Roche will pay to Bristol-Myers Squibb an upfront payment of $170 million with potential milestone payments of up to $205 million

* Bristol-Myers Squibb says Roche will pay to Bristol-Myers Squibb an upfront payment of $170 million with potential milestone payments of up to $205 million

* Bristol-Myers Squibb - Biogen also will assume all remaining obligations to former stockholders of ipierian inc related to co's acquisition of co in 2014 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐